Companies ›Healthcare ›HKPD.O

HKPD.O — NASDAQ Diversified Pharmaceuticals

Cellyan Biotechnology Co Ltd

$0,41

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

9,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,54

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Cellyan Biotechnology Co Ltd is a biotechnology company engaged in the development and commercialization of pharmaceutical products.

Business. Cellyan Biotechnology Co Ltd (HKPD.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. The company is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

UBS Financial Services, Inc.

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning HKPD.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to HKPD.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Cellyan Biotechnology Co Ltd (HKPD.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. The company is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Cellyan Biotechnology has a fully diluted share count of 23,499,986 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. The company's market price is $0.64 per share, resulting in a market capitalization of $15,039,991.04. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available for Cellyan Biotechnology, as the valuation snapshot does not include return on invested capital (ROIC), gross margins, or net margins. This lack of data limits the ability to compare the company's performance against industry benchmarks or cohort medians.

The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the diversification of its revenue streams or the extent of its international operations.

Growth trajectory data is also limited. The outlook for the current and next fiscal years is not provided, and there are no numeric deltas or revenue history to evaluate the company's growth potential.

Risk factors include the inability to assess liquidity risk, as previously noted. The company is flagged for potential liquidity issues, but no further details are available. There is no indication of dilution potential beyond the absence of a difference between basic and diluted shares.

Recent events, such as filings or transcripts, are not disclosed in the available data. Therefore, no specific recent developments can be reported.

Key takeaways

Cellyan Biotechnology has no dilution risk from stock options or convertible securities, as basic and diluted shares are equal.
The company's market capitalization is $15,039,991.04, with a share price of $0.64.
Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
Profitability metrics such as ROIC and margins are not available, limiting the ability to evaluate performance.
Revenue concentration and geographic exposure are not disclosed, making it difficult to assess diversification.
Growth trajectory and recent events are not available in the provided data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$0,41

Market cap

$15.0M

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs HKPD · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

— vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

— vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

— vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

— vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

— vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Cellyan Biotechnology Co Ltd Market data — financials · 2026-05-28

Ownership & reference

Top holders

UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

— missing data

Short positioning

179.1Kshares short+8.8% vs prior

4.2days to cover

18.6%short of daily vol

1.4Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

HKPD.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-07-29 22:34 UTCEVENTHa Price Listing HKPD remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 162 consecutive trading days (last close $0.326). cure deadline 2027-01-17 (172 days remaining).

2026-03-27FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-03-18FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2026-01-16FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-12-31FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-12-17FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-11-24FILINGCURRENT REPORT →

2025-11-12FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-10-07FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-09-11FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-08-14FILINGANNUAL REPORT →

2025-03-28FILINGREPORT OF FOREIGN PRIVATE ISSUER →

2025-01-17FILINGREPORT OF FOREIGN PRIVATE ISSUER →

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread